LASZLO TRAZKOVICH: Open Payments
NPI 1528080025 · WESTMINSTER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$441 in 20 payments from 9 companies in 2025. Trend: 2023 $420 · 2024 $228 · 2025 $441
Food & beverage: $441
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $51 |
| Alkermes, Inc. | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: INGREZZA, UZEDY, CAPLYTA, REXULTI, ARISTADA, ABILIFY MAINTENA, Qelbree, COBENFY.
Industry payments across MD — which companies pay providers there.
